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Staphylococcus epidermidis is a harmless human skin colonizer responsible for∼20% of
orthopedic device-related infections due to its capability to form biofilm. Nowadays there
is an interest in the development of anti-biofilm molecules. Marine bacteria represent a
still underexploited source of biodiversity able to synthesize a broad range of bioactive
compounds, including anti-biofilm molecules. Previous results have demonstrated that
the culture supernatant of Antarctic marine bacterium Pseudoalteromonas haloplanktis
TAC125 impairs the formation of S. epidermidis biofilm. Further, evidence supports the
hydrophobic nature of the active molecule, which has been suggested to act as a signal
molecule. In this paper we describe an efficient activity-guided purification protocol which
allowed us to purify this anti-biofilm molecule and structurally characterize it by NMR
and mass spectrometry analyses. Our results demonstrate that the anti-biofilm molecule
is pentadecanal, a long-chain fatty aldehyde, whose anti-S. epidermidis biofilm activity
has been assessed using both static and dynamic biofilm assays. The specificity of its
action on S. epidermidis biofilm has been demonstrated by testing chemical analogs
of pentadecanal differing either in the length of the aliphatic chain or in their functional
group properties. Further, indications of the mode of action of pentadecanal have been
collected by studying the bioluminescence of a Vibrio harveyi reporter strain for the
detection of autoinducer AI-2 like activities. The data collected suggest that pentadecanal
acts as an AI-2 signal. Moreover, the aldehyde metabolic role and synthesis in the
Antarctic source strain has been investigated. To the best of our knowledge, this is the first
report on the identification of an anti-biofilm molecule form from cold-adapted bacteria
and on the action of a long-chain fatty aldehyde acting as an anti-biofilmmolecule against
S. epidermidis.
Keywords: anti-biofilm, Staphylococcus epidermidis, long fatty acid aldehyde, quorum sensing,
Pseudoalteromonas haloplanktis TAC125
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INTRODUCTION
Staphylococcus epidermidis (S. epidermidis) is now being
recognized as an important opportunistic pathogen that can
cause significant problems when breaching the epithelial barrier,
especially during the biofilm-associated infection of indwelling
medical devices (Otto, 2008; Arciola et al., 2012). Most diseases
caused by S. epidermidis are of a chronic character and occur
as device-related infections (such as intravascular catheter or
prosthetic joint infections) and/or their complications (Dohar
et al., 2009; Artini et al., 2013). Implantations of medical devices
are steadily increasing and thus heightening the relevance of S.
epidermidis as a human pathogen. The ability of S. epidermidis
to adhere on both eukaryotic cells and abiotic surfaces and to
form biofilm is an essential virulence factor that contributes to
the chronicization of infections particularly difficult to eradicate.
Biofilms are sticky, surface-attached agglomerations of bacteria
that are embedded in an extracellular matrix and provide
protection for single cells from antibiotics and mechanisms of
host defense (Epstein et al., 2012).
S. epidermidis infections are estimated to reach 250,000 cases
per year in the USA with a mortality rate of up to 25%.
The interest in the development of innovative approaches for
the prevention and treatment of staphylococcal adhesion and
biofilm formation capabilities has therefore increased. A viable
approach should target the staphylococcal adhesive properties
without affecting the bacterial viability in order to avoid the rapid
appearance of escape mutants (Papa et al., 2015).
From another point of view, biofilm could be considered
as a source of novel drugs. Indeed, the specific environmental
conditions prevailing within biofilms may induce a profound
genetic and metabolic rewiring of biofilm-dwelling bacteria and
therefore may allow the production of metabolites different
from those obtained in the planktonic condition. Indeed, many
bacterial biofilms secrete molecules such as quorum sensing
signals (Ni et al., 2009), surfactants (Kiran et al., 2010), enzymes
(Kaplan, 2010), and polysaccharides (Valle et al., 2006; Qin et al.,
2009) that act by regulating the biofilm architecture or mediating
the release of cells from biofilms during the dispersal stage of the
biofilm life cycle (Kaplan, 2010). Furthermore, the production
of extracellular molecules that degrade adhesive components in
the biofilm matrix is a basic mechanism used in the biological
competition between phylogenetically different bacteria (Kaplan,
2010).
Starting from the idea that the production of an anti-biofilm
compound might result from the selective pressure exerted on
bacteria living in oligotrophic and extreme environments like
Antarctica, cold-adapted marine bacteria have been investigated
as a possible source of anti-biofilm molecules. Previous papers
(Klein et al., 2011; Papa et al., 2013b, 2015; Parrilli et al., 2015,
2016; Sun et al., 2015) have confirmed that cold adapted bacteria
represent an untapped reservoir of biodiversity able to synthesize
a broad range of potentially valuable bioactive compounds (Klein
et al., 2011), including anti-biofilm molecules (Papa et al., 2013b;
Parrilli et al., 2015, 2016).
In particular, the Antarctic bacterium Pseudoalteromonas
haloplanktis TAC125 (P. haloplanktis TAC125), when grown with
a sessile life-style, proved to be able to secrete an anti-biofilm
molecule capable of inhibiting S. epidermidis biofilm formation
(Papa et al., 2013b; Parrilli et al., 2015, 2016). This anti-biofilm
compound impairs biofilm development and disaggregates the
mature biofilm of S. epidermidis, even in dynamic conditions,
without affecting the bacterial viability, showing that its action
is specifically directed against biofilm (Papa et al., 2013b; Parrilli
et al., 2015, 2016).
In this research study the anti-biofilm molecule produced by
P. haloplanktis TAC125 has been purified and characterized. In
detail, a P. haloplanktis TAC125 biofilm cultivation in automatic
bioreactor (Parrilli et al., 2016) has been used to obtain a cell-
free supernatant in a sufficient amount to purify and characterize
the anti-biofilm molecule. A suitable purification protocol was
developed using an activity-guided fractionation strategy. The
structure of the purified molecule, obtained by NMR and mass
spectrometry, corresponded to pentadecanal, a long chain fatty
aldehyde. Several experiments were performed to assess the
chemical features responsible for its activity, by testing chemical
analogs differing in the length of the aliphatic chain and in their
functional group properties. Therefore, the anti-biofilm activity
of different long chain alcohols and aldehydes on S. epidermidis
biofilm was evaluated. As for the anti-biofilm mode of action,
the results reported demonstrated that the long-chain fatty
aldehyde works as an AI-2 signal, suggesting that it may interfere
with the S. epidermidis quorum sensing system. Moreover, in
this paper we have investigated the role of pentadecanal in
the metabolism of the source strain, in order to clarify if the
molecule regulates biofilm development also in the Antarctic
bacterium.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Bacterial strains used in this work were: S. epidermidis O-47
isolated from clinical septic arthritis and kindly provided by
Prof. Gotz (Heilmann et al., 1996); S. epidermidis RP62A
reference strain isolated from infected catheter (ATCC collection
no. 35984); P. haloplanktis TAC125 (Médigue et al., 2005)
collected in 1992 from seawater near French Antarctic Station
Dumont d’Urville. Bacteria were grown in Brain Heart Infusion
broth (BHI, Oxoid, UK) and in Tryptic Soy Broth (TSB,
Oxoid, UK). Biofilm formation was assessed in static condition
while planktonic cultures were performed under vigorous
agitation (180 rpm).
Vibrio harveyi BB170 (luxN::Tn5kan) (ATCC R©BAA-1117TM)
was grown as suggested by suppliers, cultivated in the
Autoinducer Bioassay (AB) Medium (Taga, 2005) and incubated
aerobically on a rotary shaker at 30◦C under vigorous
agitation (180 rpm).
All strains were maintained at −80◦C in cryovials with 15%
of glycerol.
Bioluminescence Assay
To screen the ability of the compounds to interfere with QS, the
test products were serially diluted in the ABmedium using sterile,
black, clear-bottom 96-well microtiter plates (Greiner Bio-one
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#655090) as assay platform. An overnight culture of V. harveyi
BB170 was diluted 1:100 in fresh AB medium and incubated
at 30◦C up to a visible increase in basal bioluminescence. 100
µl of the diluted culture were dispensed inside each well in
the microtiter plate starting from a cellular density of about
0.05 (OD)600nm; 100 µl of opportune dilutions of pentadecanal
in AB medium were added into each well. Luminescence and
(OD)600nm were monitored every 15 min over 18 h with a
high-performance multimode plate reader (GloMax R© Discover
System, Promega) in order to correlate the effects of the products
on both the growth and bioluminescence kinetics. Data are
reported as light units (LU).
Large Scale Biofilm Cultivation of
P. haloplanktis TAC125 in Automatic
Bioreactor for the Anti-Biofilm
Compound/s Production
P. haloplanktis TAC125 bacterial culture was grown in BHI
medium in a Stirred Tank Reactor 3 L fermenter (Applikon)
connected to an ADI-1030 Bio Controller (Applikon) with a
working volume of 1 L. The bioreactor was equipped with
the standard pH-, pO2-, level-, and temperature sensors for
the bioprocess monitoring. To allow the biofilm formation,
autoclaved solid polystyrene supports were added into the
bioreactor (33 supports in 1 L). The culture was carried out at
15◦C for 48 h, or at 4◦C for 96 h, in aerobic conditions using
airflow of 6 L/h, without stirring. After incubation, supports
were removed from the supernatant and the adherent cells were
recovered by sonication as previously described (Parrilli et al.,
2016). In parallel the supernatant was recovered and further
separated from cells by centrifugation at 13,000 rpm, sterilized by
filtration through membranes with a pore diameter of 0.22 µm
and stored at 4◦C until use.
P. haloplanktis TAC125 Growth in
Aerobiosis and Microaerobiosis
Batch cultivations were performed in a computer-controlled
bioreactor (Sixfors System, Infors) equipped with control units
for pH and temperature, an oxygen sensing electrode measuring
the solution oxygen pressure, and mechanical stirring (200
rpm) at 4◦C. Each fermentation unit, filled with medium and
sterilized by autoclaving, was equilibrated at process temperature.
In order to allow oxygenation of the medium, the stirring
speed was set up at the maximum value to be used during
the fermentation, and then sterile air supply was switched
on. The system was left to stabilize for at least 30 min to
guarantee the saturation of the medium with air. In these
conditions 100% of measured oxygen pressure was assigned.
The zero-point set calibration was performed by saturating the
medium with sterile nitrogen gas. Under aerobiosis conditions,
measured oxygen pressure was maintained always above 20% by
modifying stirring speed and aeration rate. In microaerobiosis
(measured oxygen pressure always below 5% saturation) air
supply was stopped after inoculum. For each strain, the growth
kinetics were followed in triplicate in at least two independent
experiments.
Molecular Methods and Reagents
Suppliers
Standard methods were employed for DNA manipulation
and isolation, amplification by PCR, and DNA sequencing.
Restriction enzymes, T4 DNA ligase, alkaline phosphatase, T4
polynucleotide kinase, Klenow fragment, Taq DNA polymerase
were supplied from Boehringer-Roche, Amersham-Pharmacia
Biotech, Promega, and New England Biolabs. DNA fragment
purification was carried out with the QUIAEX II kit from Qiagen
GmbH.
Vector pVSb0219 and P. haloplanktis
TAC125-b0219 Mutant Construction
PCR was employed to amplify a DNA fragment of PSHAb0219
gene. P. haloplanktis TAC125 genomic DNA was used as
PCR template and two primers were designed to amplify
a 275 bp-long region of the PHSAb0219 gene and to
introduce an EcoRI and a SphI site (Oligo b0219EcoRIfw
5′-CTATGAATTCAAGAAGATATTTACGAGC-3′ and Oligo
b0219SphIrv 5′-AATACCCGCATGCCGTTGGTGCC-3′). The
amplified DNA fragment was digested by EcoRI and SphI,
and inserted into the pVS plasmid (Giuliani et al., 2012)
corresponding site, thus obtaining the pVSb0219 vector.
The vector was mobilized by intergeneric conjugation into
P. haloplanktis TAC125 cells and insertion mutants were
screened on plates at 4◦C containing carbenicillin (30 µg/ml) as
selection agent.
RNA Preparation and RT-PCR
Total RNA was isolated from 500 µl aliquots of P. haloplanktis
TAC125 cells recovered from both planktonic growth and,
after sonication of supports, biofilm growth as reported in
literature (Rippa et al., 2012). RNA was reverse transcribed
using SuperScript II RNase H- reverse transcriptase (Invitrogen)
according to the manufacturer’s instructions. PHSAb0219 was
reverse transcribed starting from total RNA (∼5 µg) using as
primer-specific oligonucleotide designed on the 3′ region of
the gene (RT-PCR-Rev 5′-AATACCCGCATGCCGTTGGTGCC-
3′′). The reaction mix was denatured at 65◦C for 5 min
and reverse transcribed at 45◦C for 50 min. cDNA (275
bp), the cDNA was amplified using primers Oligo b0219
EcoRIfw 5′-CTATGAATTCAAGAAGATATTTACGAGC-3′ and
Oligo b0219 SphIrv 5′-AATACCCGCATGCCGTTGGTGCC-3′,
and Taq polymerase (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. The reaction mix was amplified
(denaturation at 95◦C for 45 s; annealing at 58◦C for 45 s;
extension at 72◦C for 1 min, 35 cycles). For each reverse
transcriptase amplification, an additional PCR reaction on DNA-
free total RNAwas performed as control, in order to exclude false
positive signals (Figure S3).
Determination of Minimal Inhibitory
Concentration (MIC)
MIC was performed according to the guidelines of Clinical
Laboratory Standards Institute. Pentadecanal was added directly
from mother stock and solutions were prepared by two-fold
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serial dilutions. A total of 5 concentrations were used
within the 1.6–0.1µg/ml range. Experiments were performed
in quadruplicate. The MIC was determined as the lowest
concentration at which the observable bacterial growth was
inhibited. No inhibition of the bacterial growth was evidenced
at testedconcentrations.
BIOFILM FORMATION OF
STAPHYLOCOCCI
Static Biofilm Assay
The quantification of in vitro biofilm production was based on
the method described by Christensen with slight modifications
(Artini et al., 2013; Papa et al., 2013a). Briefly, the wells of a sterile
48-well flat-bottomed polystyrene plate were filled with 400 µl
of BHI or TSB medium. 1/100 Dilution of overnight bacterial
cultures was added into each well. The first row contained the
untreated bacteria, while each of the remaining rows contained
serial dilutions of the supernatant (SN) starting from 1:2. The
plates were incubated aerobically for 24 h at 37◦C.
The biofilm formation was measured using crystal violet
staining. After treatment, planktonic cells were gently removed;
each well was washed three times with PBS and patted dry with
a piece of paper towel in an inverted position. To quantify the
biofilm formation, each well was stained with 0.1% crystal violet
and incubated for 15 min at room temperature, rinsed twice
with double-distilled water, and thoroughly dried. The dye bound
to adherent cells was solubilized with 20% (v/v) glacial acetic
acid and 80% (v/v) ethanol. After 30 min of incubation at room
temperature, (OD) was measured at 590 nm to quantify the
total biomass of biofilm formed in each well. Each data point is
composed of three independent experiments, each performed at
least in 3-replicates.
Dynamic Biofilm Assay
To continuously monitor the biofilm development in dynamic
condition, we utilized a BioFlux 2,000 microfluidic system
(Fluxion Biosciences Inc., San Francisco, CA), which allows
the acquisition of microscopic images over time using the
experimental protocol previously set up (Iebba et al., 2014). Each
flow channel connects to an input well (inlet) and an output
well (outlet) on the plate. To grow the biofilm in the BioFlux
system, the channels were first primed. We have filled the outlet
with 100 µl of sterile distilled water and set the flow at a share
setting of 1 dyne/cm2 for 2min. Coating with 100 µl of 10 µg/ml
fibronectin was made for 2 min at 1 dyne/cm2. The fibronectin
binding was performed for 30 min without flow. After priming,
fibronectin was aspirated from the output wells and replaced with
100 µl of fresh overnight cultures diluted to an (OD)600 of 0.8.
The channels were seeded by pumping from the output wells
to the input wells at 2.0 dyne/cm2 for 4 sec. Bacterial adhesion
was performed for 30 min at 37◦C without flow. 2.0 mL of BHI
was added to the input well and pumped at 1 dyne/cm2 for 12
h. We used two inlet wells; in the first well we added only BHI.
In the second well we added pentadecanal at a concentration of
120 µg/ml. Bright-field images were taken at 40X magnification
at 1-min intervals for a total of 720 time points.
Anti-Biofilm Molecule Purification and
Identification
As reported in the previous paper (Parrilli et al., 2016),
P. haloplanktis TAC125 supernatant deriving from sessile growth
was dialyzed, and the permeated water (2 g) was then purified on
a gel-filtration column (Biorad, Biogel P-2) eluted with MilliQ
water. The active fractions were collected and fractionated
on a C18 reverse phase column (Sigma, 30 mL, 40 × 0.5 cm,
fraction volume 4mL), eluted with CH3CN:H2O ranging from
10 to 95% of CH3CN. The fraction resulted to be active (S) was
analyzed on a Agilent Technologies gas chromatograph 6850A
equipped with a mass selective detector 5973N and a Zebron
ZB-5 capillary column (Phenomenex, 30m × 0.25 mmi.d.,
flow rate 1 cm3/min, He as carrier gas), by using the following
temperature program: 150◦C for 3 min, from 150 to 300◦C at
15◦C/min, at 300◦C for 5min.
NMR Spectroscopy
NMR spectra were performed by using a Bruker Avance-DRX
600 MHz spectrometer equipped with a cryoprobe. 1H-1HDQF-
COSY, 1H-1HTOCSY, 1H-13CDEPT-HSQC, and 1H-13CHMBC
experiments were recorded at 298K in CDCl3. The mixing time
for TOCSY experiment was 100 ms.
Fatty Aldehydes Chemical Synthesis
C14-C16 aldheydes were purchased from TCI. All the
other tested compounds were synthesized starting from the
corresponding alcohols (Sigma). 1- heptadecanol (30 mg, 0.12
mmol) was charged into a 10 mL round-bottom flask equipped
with a magnetic stir bar. The solid was then dissolved in toluene
(2 mL) at 20◦C, and an aqueous solution of sodium bicarbonate
(0.2 g, 2.38 mmol in 2 mL of deionized water) was prepared
and charged into the toluene slurry. Solid iodine (2.0 eq., 60
mg, 0.24 mmol) was then charged to the alcohol followed by
solid TEMPO (0.1 eq., 1.87 mg, 12.0 µmol; Miller and Hoerrner,
2003). The reaction mixture was then left under stirring for 16 h
at 20◦C. The batch was cooled to 5◦C, diluted with ethyl acetate
(2 mL), and quenched at 5◦C by adding an aqueous solution of
sodium sulfite 10% (312mg sodium sulfite in 2 mL of deionized
water). The quenched reaction mixture was transferred into
a separatory funnel, rinsed with additional ethyl acetate (10
mL) and deionized water (10 mL), and the aqueous layer was
cut away. The organic layer was then washed with 10 mL of
saturated aqueous sodium bicarbonate, followed by 10 mL of
brine. The organic layer was then dried over sodium sulfate,
filtrated, and concentrated in vacuum to a volume of 4 mL. Then,
the solution was completely dried under a stream of argon, to
give the aldehyde with a 95% yield.
The same procedure was then utilized for the alcohols 1-
octadecanol, 1-nonadecanol, and 1-eicosanol for the obtainment
of the corresponding aldehydes.
Statistics and Reproducibility of Results
The data reported were statistically validated using the Student’s
t-test comparing the mean absorbance of treated and untreated
samples. The significance of differences between the mean
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absorbance values was calculated using a two-tailed Student’s
t-test. A p < 0.05 was considered significant.
Bacterial Viability and Biofilm Thickness
Determined by Confocal Laser Scanning
Microscopy
For confocal microscopy biofilms were formed on Nunc
TM
Lab-Tek R© 8-well Chamber Slides (n◦ 177445; Thermo
Scientific, Ottawa, ON, Canada). Briefly, overnight cultures
of S. epidermidis O-47 and RP62A grown in BHI were diluted
and inoculated into each well of the chamber slide to a cell
concentration of about 0.001 (OD)600nm. The bacterial cultures
were incubated at 37◦C for 20 h in presence of pentadecanal (100
µg/ml) in order to assess its anti-biofilm activity and its influence
on cell viability.
The biofilm cell viability was determined with the
FilmTracerTM LIVE/DEAD R© Biofilm Viability Kit (Molecular
Probes, Invitrogen, Carlsbad, California) following the
manufacturer’s instructions. After rinsing with filter-sterilized
PBS, each well of the chamber slide were filled with 300 µl of
working solution of fluorescent stains, containing the SYTO R©
9 green fluorescent nucleic acid stain (10 µM) and Propidium
iodide, the red-fluorescent nucleic acid stain (60 µM), and
incubated for 20–30 min at room temperature, protected from
light. All excess stain was removed by rinsing gently with
filter-sterilized PBS.
All microscopic observations and image acquisitions were
performed with a confocal laser scanning microscope (CLSM;
LSM700-Zeiss, Germany) equipped with an Ar laser (488 nm),
and a He-Ne laser (555 nm). Images were obtained using a
20X/0.8 objective. The excitation/emission maxima for these
dyes are ∼480/500 nm for SYTO R© 9 stain and 490/635 nm
for propidium iodide. Z-stacks were obtained by driving the
microscope to a point just out of focus on both the top and
bottom of the biofilms. Images were recorded as a series of.tif files
with a file-depth of 16 bits. For each condition, two independent
biofilm samples were used.
RESULTS
Anti-Biofilm Production and Purification
We have previously (Papa et al., 2013b; Parrilli et al., 2015)
demonstrated that the cell-free supernatant of the Antarctic
bacterium P. haloplanktis TAC125 inhibits S. epidermidis biofilm
formation and that the bacterium produces the active molecule
only when it is grown in a sessile condition (Papa et al., 2013b). To
obtain a sufficient amount of cell-free supernatant, we adopted
a recently described (Parrilli et al., 2016) biofilm cultivation
strategy for P. haloplanktis TAC125. This consists in a fluidized-
bed reactor fermentation in the presence of floating polystyrene
supports used to increase the biofilm formation (Parrilli et al.,
2016). In this work the Antarctic bacterium has been grown
in the presence of floating polystyrene supports in BHI in a 3
L tank reactor at 4◦C without stirring, using an airflow of 6 L
h−1 (see materials and Methods Section). The obtained cell-free
supernatant was recovered after 96 h and separated from the
floating polystyrene supports and the cells by a centrifugation
at 13,000 rpm. Subsequently the supernatant was sterilized by
filtration through membranes with a pore diameter of 0.22 µm,
and then underwent dialysis treatment using a semipermeable
membrane with a cut-off of 3.5 KDa. The permeate product
after lyophilization was fractionated on a Biogel P-2 column and
the anti-biofilm activity of each fraction was evaluated (data not
shown). The fraction endowed with anti-biofilm activity on S.
epidermidis O-47 was further purified on a C18 reverse phase
column eluted with acetonitrile/water. Several fractions (A–S)
were collected, and the anti-biofilm activity of each fraction
was tested as reported in Figure 1A. Fraction S, eluted with
95% acetonitrile, showed the highest inhibitory activity on S.
epidermidis biofilm. The analysis of the 1H NMR spectrum of
this fraction revealed a signal at δ 9.77 ppm, which immediately
suggested the presence of an aldehyde (MOLBASE.COM CAS.
No. 2765-11-9). This was believed to be aliphatic, due to the
presence of intense signals in the range between δ 0.1–2.5 ppm
(data not shown). To confirm this hypothesis, and to check
the purity of the sample, a GC-MS analysis was performed
(Figure 1B). The chromatogram clearly indicated two different
compounds, named A and B, the EI mass spectra of which are
reported (Figures 1C,D). Both spectra showed signals at m/z 43,
57, 71, and 85, that are typical of a straight chain hydrocarbon
backbone, thus confirming the aliphatic character of the two
molecules. As this type of fragmentation can be attributed to a
broad range of compounds, a research in the NIST library was
required. The results indicated with a high score a 2-tridecanone
and a pentadecanal for A and B, respectively. As the inactive
fraction Qmainly contains the ketone whereas fraction S shows a
higher content of the pentadecanal, we concluded that the activity
should be assigned to the aldehyde. To exclude the possibility
that the mass spectrum of B could belong to an aldehyde with
a short difference in the carbon chain length, we injected into
the gas chromatograph commercial C14-C16 aldehydes. The
retention time of compound B proved to correspond to that of
pentadecanal.
To confirm the data obtained from GC-MS, the S fraction
was analyzed by 2D-NMR spectroscopy. In particular,
two-dimensional 1H-1H DQF-COSY (double quantum-
filtered correlation spectroscopy), 1H-1H TOCSY (total
correlation spectroscopy), 1H-13C DEPT-HSQC (distortionless
enhancement by polarization transfer-heteronuclear single
quantum coherence), and 1H-13C HMBC (heteronuclear
multiple bond correlation) experiments were performed. The
proton at δ 9.79 ppm, that clearly indicated an aldehyde
functional group on the molecule, displayed a correlation with
a carbon at δ 203.1 ppm (Figure 2A; data not shown). In turn,
this carbon showed a long range scalar connectivity with protons
at δ 2.43 ppm (CH2,C2; Figure 2B). Starting from this proton
signal, the correlations revealed in the COSY and TOCSY spectra
allowed us to attribute all the CH2(C3-C14) that constitute the
aliphatic chain. The last signal, attributable to the CH2C14 (δH/C
1.36/22.9), showed a long-range cross-peak, with the methyl
group at δH/C 0.9/13.6 ppm (Figure 2C).
A confirmation of the correct assignment of the pentadecanal
structure was obtained by testing the commercial product on
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FIGURE 1 | Anti-biofilm assay and identification by GC-MS analysis. (A) The anti-biofilm activity of different fractions obtained from reverse phase C18 column.
The fraction S eluted with 95% acetonitrile showed the highest inhibition activity. (B) GC-MS chromatogram of the fraction S. (C) Mass spectrum of compound A, and
(D) compound B.
FIGURE 2 | Relevant sections of 1H-13C HSQC spectrum, recorded in CDCl3 at 298K at 600MHz. (A) The correlation at δ 9.79/203.1 ppm, clearly indicated
the aldehydic functional group of the molecule. (B) The carbon signal at δ 203.1 ppm is in turn correlated in the HMBC experiment (data not shown), with the protons
at δ 2.43 ppm (CH2 C2). (C) The attribution of the aliphatic chain (C3–C15).
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S. epidermidis biofilm, that was found to be active (Figure 3A).
Consequently, commercial pentadecanal was used for all further
experiments.
Anti-Biofilm Activity and Specificity of
Pentadecanal on S. epidermidis Biofilm
Once the structure of the anti-biofilm molecule had been
identified, the first step was to confirm the absence of any
antimicrobial activity of pentadecanal on the staphylococcal
reference strains by determining the minimum inhibitory
concentration. The data obtained indicated no bacteriostatic
and no bactericidal activity within the range of concentrations
explored (the highest concentration explored was 1,6 mg/ml).
Preliminary experiments were also carried out to assess the effects
of the molecule on the planktonic growth rate of S. epidermidis.
The results obtained showed that pentadecanal did not affect
the staphylococcal duplication rate. Bacterial growth curves were
superimposable both in the presence and absence of pentadecanal
(data not shown).
The pentadecanal activity on biofilm formation was assessed
on two different S. epidermidis strains (Figure 3A), according
to previously reported data that demonstrated the cell-free
FIGURE 3 | Pentadecanal anti-biofilm activity on S. epidermidis biofilm formation. (A) The effect of pentadecanal at different concentrations on biofilm
formation of S. epidermidis O-47 and S. epidermidis RP62A. The data are reported as percentages of residual biofilm. Each data point is composed of three
independent samples. (B) Biofilm formation of S. epidermidis O-47 in a BioFlux system in the presence of pentadecanal. Each image contains two channels: the
bottom channel is the pentadecanal-treated sample and the top channel is the control. Bright-field microscopic images were collected at 1-min intervals. The images
presented were taken from the complete set of 720 images taken at 40x magnification.
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supernatant activity of P. haloplanktisTAC125 against the
S. epidermidis O-47 and S. epidermidis RP62A biofilms (Papa
et al., 2013b). As expected, the pentadecanal inhibitory effect was
clearly dose-dependent with an efficacy higher than 50% already
at 60µg/ml (50.9% residual biofilm for S. epidermidis O-47 and
21.8% for S. epidermidis RP62A, respectively). All previously
described experiments were performed in BHI medium. The
pentadecanal anti-biofilm activity was also tested in TSBmedium
to verify its effectiveness in function of growth medium
composition. The results demonstrated that this latter did not
influence the anti-biofilm ability of pentadecanal (untreated
bacteria 0.761± 0.137; treated bacteria 0.152± 0.020).
The pentadecanal anti-biofilm efficacy was also tested in
dynamic conditions with the BioFlux system, a microfluidic
device that precisely controls the flow of growthmedium between
two interconnected wells of a microtiter plate. By positioning
the channel connecting the two wells over a window accessible
for viewing by microscopy, biofilm growth can be monitored
in a time-course assay in which images are collected at 1-min
intervals. In Figure 3B selected images of the BioFlux analysis
are reported, showing the biofilm development of S. epidermidis
O-47 at different times, in the absence or in the presence of
pentadecanal (top and bottom lanes of each panel, respectively).
The bacteria were seeded in both channels visible in each frame
and after 30 min the flow was applied. The images collected
showed an initial rapid growth of the bacteria, resulting in
a confluent “lawn” of cells that was followed by a period of
detachment. Pentadecanal clearly impaired the biofilm formation
confirming the results obtained in the static system.
The pentadecanal effect on S. epidermidis O-47 biofilm
was further investigated by confocal laser scanning microscopy
(Figures 4A–D). CLSM was used to analyse the biofilm structure
and viability, as shown in Figures 4B,D. In the presence
of pentadecanal, as expected, the biofilm thickness decreased
significantly with a notable alteration in the architecture. This
effect was evident both on S. epidermidis O-47 biofilm and on
S. epidermidis RP62A biofilm. Moreover, the viability of cells
encapsulated in the biofilm in the presence and in the absence
of pentadecanal was evaluated by live/dead staining. As shown
in Figure 4C, cells exposed to pentadecanal were alive (green
indicates viable cells while red indicates dead cells) confirming
that the long-chain fatty aldehyde had no bactericidal activity on
the S. epidermidis cells living in the biofilm.
In order to investigate the chemical features (the length of
the chain and the functional group nature) that are essential
for the anti-biofilm activity, the effect of similar aldehydes and
corresponding alcohols, characterized by different lengths of the
aliphatic chain in the range fromC-14 to C-20, were analyzed and
the results are summarized in Figure 5. The data are reported as
percentages of residual biofilm after the treatment in comparison
FIGURE 5 | Anti-biofilm activity of different aldehydes and alcohols on
S. epidermidis O-47. The anti-biofilm activity of different long-chain aldehydes
and alcohols on S. epidermidis O-47. The data are reported as percentages of
residual biofilm. Each data point is composed of four independent samples.
FIGURE 4 | CLSM of S. epidermidis O-47 and S. epidermidis RP62A biofilms in the presence and absence of pentadecanal. (A) CLSM of S. epidermidis
O-47 and S. epidermidis RP62A biofilms in BHI medium without pentadecanal and (C) with pentadecanal 100 µg/ml. The bacteria were grown in chamber slides for
20 h and then stained with LIVE/DEAD reagents. The green fluorescence (SYTO9) indicates viable cells PI and the red fluorescence (PI) indicates dead cells. (B)
Z-stack analysis of S. epidermidis O-47 and RP62A biofilms without pentadecanal. (D) Z-stack analysis of S. epidermidis O-47 and RP62A biofilms treated with 100
µg/ml pentadecanal.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 February 2017 | Volume 7 | Article 46
Casillo et al. Anti-Biofilm Long-Chain Fatty Aldehyde
with the untreated biofilm of S. epidermidis O-47. Our results
clearly showed that, except for a partial reduction observed after
treatment with the alcohol at the C-14 chain, the anti-biofilm
activity was limited to pentadecanal.
Pentadecanal As an AI-2 Signaling
Molecule in the LuxS/AI-2 QS System
To test whether the anti-biofilm activity displayed by
pentadecanal is correlated with a modulation/activation of
the AI-2 quorum sensing system, the effect of pentadecanal
was investigated on a V. harveyi BB170 strain (luxN::tn5Kan), a
mutant sensor strain that responds only to AI-2 autoinducers.
TheV. harveyiBB170 bioluminescence wasmonitored (Figure 6)
after adding two different concentrations of pentadecanal. At
a low concentration (12.5 µg/ml) the pentadecanal was
able to increase the V. harveyi bioluminescence (Figure 6),
indicating that the V. harveyi LuxS/AI-2 QS system responds
to pentadecanal. At a higher concentration (200 µg/ml)
pentadecanal reduced the bioluminescence (Figure 6). In
this condition, pentadecanal probably inhibits the V. harveyi
luciferase. Since the V. harveyi luciferase physiological substrate
is tetradecanal (Ulitzur and Hastings, 1979), the bioluminescence
inV. harveyiBB170 was alsomonitored after adding two different
concentrations of tetradecanal (Figure S1). As expected, a higher
concentration (200µg/ml) of tetradecanal reduced theV. harveyi
bioluminescence due to the luciferase substrate inhibition, at
low concentrations tetradecanal had no effect on the V. harveyi
bioluminescence (Figure S1).
The Role of Pentadecanal in the
P. haloplanktisTAC125 Physiology
To assess the role of pentadecanal in the P. haloplanktisTAC125
physiology, we investigated the conditions necessary for
pentadecanal production and the possible synthetic pathway
involved.
The in silico analysis of the P. haloplanktisTAC125 genome
(EMBL under accession nos. CR954246 and CR954247).
did not allow us to identify the genes coding for enzymes
known to be able to synthesize fatty aldehydes, like fatty acid
reductase (EC 1.2.1.50 (Gahan, 2012) or fatty acid peroxidase
(EC1.11.1.3, Martin and Stumpf, 1959). However, the analysis
allowed the identification of a gene (PSHAb0219) coding for an
aldehyde dehydrogenase B (EC1.2.1.3), an enzyme annotated
as a reversible aldehyde oxidoreductase NAD(P)+-dependent
with a wide specificity (http://www.genoscope.cns.fr/agc/
microscope/mage/viewer.php). The aldehyde oxidoreductase,
in specific conditions, could be able to produce pentadecanal
by reducing the corresponding fatty acid. To assess if this was
a correct hypothesis, we first investigated the presence of the
pentadecanoic acid in P. haloplanktis TAC125 cells. A GC-MS
analysis of fatty acid methyl esters from P. haloplanktis TAC 125
cells, grown either in sessile or in planktonic conditions, revealed
the presence of pentadecanoic acid (Figure S2).
Once the presence of the possible substrate had been
verified, both in sessile and in planktonic conditions, a RT
PCR analysis of the PSHAb0219 gene was performed to
assess if the gene transcription is growth condition-dependent.
P. haloplanktis TAC125 cells were cultured in planktonic or
in sessile conditions and total RNA was extracted from the
two different samples. The PSHAb0219 gene amplification was
obtained with specific oligonucleotide pairs (see Material and
Methods Section). The results of the RT-PCR experiments
(Figure S3) showed that a PSHAb0219 gene transcription
was clearly detected in the RNA samples extracted from
P. haloplanktis TAC125 cells grown in both conditions. Several
experiments were then attempted to delete the PSHAb0219 gene
by using genetic tools for the creation of insertion/deletion
FIGURE 6 | V. harveyi LuxS/AI-2 QS system responds to the presence of pentadecanal. Bioluminescence (solid lines) and growth curves (dotted lines) of the
V. harveyi BB170 strain incubated for 20 h in the presence of only the AB medium (green lines), 12.5 µg/mL pentadecanal (black lines) and 200 µg/mL pentadecanal
concentrations (red lines).
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 February 2017 | Volume 7 | Article 46
Casillo et al. Anti-Biofilm Long-Chain Fatty Aldehyde
mutants already available (Parrilli et al., 2010). However, these
experiments were not successful probably due to the fact
that PSHAb0219, in tested conditions, is likely to be an
essential gene.
Since the pentadecanoic acid was produced in both sessile and
planktonic conditions and the PSHAb0219 gene was transcribed
in both settings, a possible explanation of the presence of
pentadecanal only in the supernatant of the sessile form could
be that the aldehyde oxidoreductase catalyses the reduction of
the acid to aldehyde only in the biofilm condition. In particular,
in oxygen limitation, a condition occurring in biofilm (Wessel
et al., 2014), bacterial cells could reduce the fatty acids in
order to obtain the oxidized cofactor (NAD(P)+) necessary
for cell metabolism. To verify this hypothesis P. haloplanktis
TAC125 cells were grown, in an automatic bioreactor, at 4◦C
in microaerobiosis under agitation, a condition where the
measured oxygen pressure is kept constantly below 5% saturation
(measured oxygen pressure <5%)(see Materials and Methods
Section). The anti-biofilm activity of the cell-free supernatant
of P. haloplanktis TAC125 grown in microaerobiosis (SN-M)
was tested on S. epidermidis biofilm. The SN-M proved to
be able to inhibit the S. epidermidis O-47 biofilm formation
(Figure 7), thus indicating that the pentadecanal production
occurs also in microaerobiosis. This experiment demonstrates
that oxygen availability is a crucial parameter for pentadecanal
synthesis and proves to be the main difference between sessile
and planktonic conditions, so determining the anti-biofilm
production.
Although pentadecanal could be not defined as a strictly
biofilm-specific metabolite, its effect on P. haloplanktis
TAC125 biofilm formation and development was tested.
The aldehyde presence proved to have no effect (Figure
S4) on the Antarctic bacterium biofilm development.
Moreover, pentadecanal proved to be inactive against
the mature biofilm of P. haloplanktis TAC125 (data
not shown).
FIGURE 7 | The cell-free supernatant of P. haloplanktis TAC125 grown
in microaerobiosis has an anti-biofilm activity S. epidermidis O-47 biofilm
formation after incubation with P. haloplanktis TAC125 cell-free supernatants
obtained from sessile (SN-S) and planktonic growths (SN-P) and from
microaerobiosis growth (SN-M). The data are reported as percentages of
residual biofilm. Each data point represents the mean ± SD of at least three
independent samples.
DISCUSSION
The emergence of Staphylococcus epidermidis as an opportunistic
pathogen is closely related to the biofilm forming capability of
this bacterial species, especially during the biofilm-associated
infection of indwelling medical devices. The increasing use
of implanted medical devices heightens the importance of S.
epidermidis as a human pathogen. Our research has been aimed
at discovering anti-biofilm molecules from natural sources, such
as marine microbiota, since we are convinced that this approach
will lead to the discovery of novel and unforeseen compounds.
Cold-adapted marine bacteria represent a still underexploited
source of biodiversity able to synthesize a broad range of bioactive
compounds, including anti-biofilm molecules. Previous results
(Papa et al., 2013b; Parrilli et al., 2015) have demonstrated
that the culture supernatant of Antarctic marine bacterium
P. haloplanktis TAC125 impairs the formation of S. epidermidis
biofilm.
In this paper we applied a P. haloplanktis TAC125 biofilm
cultivation strategy in automatic bioreactor (Parrilli et al., 2016)
and an efficient activity-guided purification protocol to produce
and purify the anti-biofilm molecule. The structure of the anti-
biofilm molecule, obtained by NMR and mass spectrometry,
corresponds to pentadecanal, a long-chain fatty aldehyde.
The pentadecanal activity on biofilm formation was confirmed
on two different S. epidermidis strains in static condition and,
by the BioFlux system, also in dynamic conditions. BioFlux
can reproduce environmental or physiological conditions by
precisely controlling shear flow, bridging the gap between in
vitro and in vivo assays. In Bioflux conditions bacteria progress
through a series of developmental steps, ultimately forming a
multicellular structure containing differentiated cell populations.
The observation of the growing biofilm at various time-points
throughout this process provides a glimpse of the temporal
changes that occur. Flow biofilm is more closely related to
natural biofilms and can differ from static biofilms in terms of
the hydrodynamic influences on cell signaling. The finding that
pentadecanal is active also in dynamic conditions demonstrates
that this molecule shows great promise in terms of its use in vivo
systems.
It is interesting to note that most of the known anti-biofilm
molecules also display an antibacterial activity (bactericidal or
bacteriostatic). In contrast, pentadecanal lacks any antibacterial
activity against free-living bacteria and against bacteria entrapped
in biofilm matrix. Indeed as demonstrated by CLSM analysis the
presence of pentadecanal reduces the biofilm thickness without
affecting the viability of S. epidermidis cells living in the biofilm.
Therefore, pentadecanal targets the adhesive properties without
affecting the bacterial viability, a type of behavior which should
prevent the development of escape mutants. This property makes
pentadecanal particularly interesting and suggests its possible use
in combination with conventional antibiotic therapy.
The specificity of pentadecanal action on S. epidermidis
biofilm has been demonstrated by testing chemical analogs
differing either in the length of the aliphatic chain or in their
functional group properties. The results reported demonstrate
that both the length of the aliphatic chain and the functional
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group properties are essential for the pentadecanal activity
against S. epidermidis biofilm.
With regard to the anti-biofilm mode of action, several
observations prompted us to explore the idea that the action
of pentadecanal on S. epidermidis biofilm could be related to
its possible interference in the quorum sensing system. The
most important and best-characterized quorum-sensing system
in staphylococci is the accessory gene regulator (agr) system.
Remarkably, the P. haloplanktis TAC125 anti-biofilm molecule is
active on the clinical isolate O-47, which is a naturally occurring
agr mutant (Vuong et al., 2003); therefore a possible effect
mediated by quorum sensing should be directed at the LuxS/AI-
2 quorum sensing system (Xu et al., 2006; Li et al., 2008), the
second quorum sensing system present in S. epidermidis. The role
of the LuxS/AI-2 QS system in S. epidermidis biofilm regulation
is under debate. Xu and co-authors have suggested that the
autoinducer 2 (AI-2) negatively regulates the expression of the ica
gene [ica operon encodes enzymes responsible for the production
of polysaccharide intercellular adhesion PIA (Otto, 2008)] at
the transcriptional level, reducing the PIA synthesis and biofilm
formation (Xu et al., 2006). In contrast, a recent paper of Xue
et al. (2015) has reported that AI-2 increased biofilm formation
in S. epidermidis RP62A by enhancing the transcription of the
ica operon. Moreover, in a paper (Li et al., 2008) concerning
AI-2 dependent gene regulation in S. epidermidis, it has been
demonstrated that AI-2 controls also the levels of phenol-
soluble modulins (PSMs), key molecules able to lead to biofilm
detachment of S. epidermidis biofilm in vivo e in vitro (Otto,
2013). In any case, the crucial role of the LuxS/AI-2 QS system
in S. epidermidis biofilm formation is evident, while its role in
Staphylococcus aureus biofilm formation is less clear; indeed,
several studies suggest that the LuxS/AI-2 quorum sensing
system has no role in S. aureus biofilm formation (Doherty et al.,
2006; Cluzel et al., 2010). The differences in the involvement of
AI-2 molecules in biofilm formation between S. aureus and S.
epidermidis could explain why the P. haloplanktis TAC125 anti-
biofilm compound is effective against the S. epidermidis biofilm
but is not able to inhibit the S. aureus biofilm (Papa et al.,
2013b). To test whether the anti-biofilm activity displayed by
pentadecanal is correlated with a modulation/activation of the
AI-2 quorum sensing system, the effect of pentadecanal was
investigated on a V. harveyi mutant sensor strain that responds
only to the AI-2 autoinducers.
The results reported demonstrate that at low concentration
the pentadecanal is able to increase the V. harveyi
bioluminescence, indicating that the V. harveyi LuxS/AI-2
QS system responds to pentadecanal, at a higher concentration
it reduces the bioluminescence. In this condition, pentadecanal
probably inhibits the V. harveyi luciferase. The key reaction
in bacterial bioluminescence is the oxidation of the luciferase-
catalyzed FMNH2 and the long chain aliphatic aldehyde (Byers
et al., 1988), and, consequently, the bacterial luciferase, that can
utilize fatty aldehydes of varying chain lengths, is inhibited by
the high levels of aldehydes (Francisco et al., 1993). Therefore,
it is reasonable to assume that also pentadecanal could be
an inhibitor of the V. harveyi luciferase. Since the V. harveyi
luciferase physiological substrate is tetradecanal (Ulitzur and
Hastings, 1979), the bioluminescence in V. harveyi mutant was
also monitored in presence of tetradecanal, and, as expected, a
higher concentration reduced the V. harveyi bioluminescence
due to the luciferase substrate inhibition. It is interesting to note
that at low concentrations tetradecanal had no effect on the
V. harveyi bioluminescence.
The results reported demonstrate that theV. harveyi LuxS/AI-
2 QS system responds to pentadecanal. These data suggest
that the pentadecanal anti-biofilm activity in S. epidermidis
could be due to an interference in the AI-2 quorum sensing
system. Although several studies will be necessary to clarify the
molecular details of the pentadecanal action on S. epidermidis
biofilm formation, this is the first report on the action of
a long-chain fatty aldehyde as an anti-biofilm molecule that
works as a signaling molecule in an AI-2 QS system. Further
investigations will be necessary to clarify if this modulation
occurs also in the S. epidermidis AI-2 quorum sensing
system.
Besides the characterization of pentadecanal anti-biofilm
activity on S. epidermidis biofilm, we have investigated the
metabolic role and synthesis of this long fatty compound in
the Antarctic source strain. In a previous work we examined
the anti-biofilm activity of cell-free supernatants obtained from
the P. haloplanktis TAC125 grown in sessile or in planktonic
conditions on different staphylococci (Papa et al., 2013b). Our
results demonstrated that only when P. haloplanktisTAC125
is grown in sessile condition the cell-free supernatant inhibit
the biofilm formation of S. epidermidis. This latter result was
explained by considering that biofilm specific environmental
conditions may induce a profound genetic and metabolic
rewiring allowing the production of biofilm-specific metabolites
(Beloin and Ghigo, 2005). To evaluate if pentadecanal can
be considered a biofilm-specific metabolite, we investigated
the conditions necessary for pentadecanal production and
the possible synthetic pathway involved. The results reported
strongly suggest that a P. haloplanktisTAC125 reversible
aldehyde oxidoreductase NAD(P)+-dependent catalyses, in
oxygen limitation, the reduction of the pentadecaonic acid to
aldehyde to obtain the oxidized cofactor (NAD(P)+) necessary
for cell metabolism. Therefore, the pentadecanal production
occurs in the biofilm condition and in microaerobiosis due to the
reduced oxygen availability that characterizes these two growth
conditions. The oxygen availability results a crucial parameter
for pentadecanal synthesis and proves to be the main difference
between sessile and planktonic conditions, so determining the
anti-biofilm production. Moreover, the results described in this
paper indicate that the long-chain fatty aldehyde is not involved
in the control/modulation of the Antarctic bacterium biofilm
development.
In conclusion, this is the first report both on the action of a
long chain fatty aldehyde as an anti-biofilm molecule and on an
aldehyde working as a signaling molecule in the AI-2 QS system.
We believe that this paper endorses the potential of cold-adapted
marine bacteria as a source of bioactive compounds of interest,
and contributes to the development of innovative approaches for
the prevention and treatment of S. epidermidis biofilm-associated
infections.
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